Tyrosinemia Type 1 Latest Advances

A optimized engineered bacterium for tyrosinemia type 1 therapy: A multi-species preclinical study.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: January 07, 2026

In Vivo Confocal Microscopy and Anterior Segment Optical Coherence Tomography Features of Corneal Pseudodendritic Lesions in Hereditary Tyrosinemia Type 1.

Journal: The American journal of case reports

Published: December 27, 2025

SIADH as an Underrecognized Manifestation of Porphyria-like Crises in Hereditary Tyrosinemia Type 1: Clinical and Pathophysiological Insights.

Journal: International journal of molecular sciences

Published: December 20, 2025

Untargeted Metabolomics Reveals Metabolic Reprogramming Linked to HCC Risk in Late Diagnosed Tyrosinemia Type 1.

Journal: Metabolites

Published: November 24, 2025

Quantitative Succinylacetone Measurement by Gas Chromatography-Tandem Mass Spectrometry (GC-MS/MS) Facilitates Diagnosis, Monitoring, and Characterization of Tyrosinemia Type 1 and Other Hypersuccinylacetonemias.

Journal: JIMD reports

Published: October 29, 2025

Correction: Kuypers et al. Evaluation of Neonatal Screening Programs for Tyrosinemia Type 1 Worldwide. Int. J. Neonatal Screen. 2024, 10, 82.

Journal: International journal of neonatal screening

Published: June 27, 2025

Overview of European Practices for Management of Tyrosinemia Type 1: Towards European Guidelines.

Journal: Journal of inherited metabolic disease

Published: June 24, 2025

Hereditary Tyrosinemia Type 1: Success and Challenges in Indian Subcontinent.

Journal: Indian pediatrics

Published: June 16, 2025

Management of porphyria-like syndrome in tyrosinemia type 1.

Journal: Journal of pediatric endocrinology & metabolism : JPEM

Published: June 03, 2025

Evaluation of the Performance of Newborn Screening for Tyrosinemia Type 1 in The Netherlands: Suggestions for Improvements Using Additional Biomarkers in Addition to Succinylacetone.

Journal: International journal of neonatal screening

Published: April 09, 2025

Integrating Machine Learning and Follow-Up Variables to Improve Early Detection of Hepatocellular Carcinoma in Tyrosinemia Type 1: A Multicenter Study.

Journal: International journal of molecular sciences

Published: March 06, 2025

Neurological crisis in tyrosinemia type 1: Essential roles of replacement therapy and nutrition in multidisciplinary management.

Journal: Endocrinologia, diabetes y nutricion

Published: February 16, 2025

Tyrosinemia Type 1 Latest Advances

Find the Latest Research About Tyrosinemia Type 1

A optimized engineered bacterium for tyrosinemia type 1 therapy: A multi-species preclinical study.

A optimized engineered bacterium for tyrosinemia type 1 therapy: A multi-species preclinical study.

In Vivo Confocal Microscopy and Anterior Segment Optical Coherence Tomography Features of Corneal Pseudodendritic Lesions in Hereditary Tyrosinemia Type 1.

In Vivo Confocal Microscopy and Anterior Segment Optical Coherence Tomography Features of Corneal Pseudodendritic Lesions in Hereditary Tyrosinemia Type 1.

SIADH as an Underrecognized Manifestation of Porphyria-like Crises in Hereditary Tyrosinemia Type 1: Clinical and Pathophysiological Insights.

SIADH as an Underrecognized Manifestation of Porphyria-like Crises in Hereditary Tyrosinemia Type 1: Clinical and Pathophysiological Insights.

Untargeted Metabolomics Reveals Metabolic Reprogramming Linked to HCC Risk in Late Diagnosed Tyrosinemia Type 1.

Untargeted Metabolomics Reveals Metabolic Reprogramming Linked to HCC Risk in Late Diagnosed Tyrosinemia Type 1.

Quantitative Succinylacetone Measurement by Gas Chromatography-Tandem Mass Spectrometry (GC-MS/MS) Facilitates Diagnosis, Monitoring, and Characterization of Tyrosinemia Type 1 and Other Hypersuccinylacetonemias.

Quantitative Succinylacetone Measurement by Gas Chromatography-Tandem Mass Spectrometry (GC-MS/MS) Facilitates Diagnosis, Monitoring, and Characterization of Tyrosinemia Type 1 and Other Hypersuccinylacetonemias.

Correction: Kuypers et al. Evaluation of Neonatal Screening Programs for Tyrosinemia Type 1 Worldwide. Int. J. Neonatal Screen. 2024, 10, 82.

Correction: Kuypers et al. Evaluation of Neonatal Screening Programs for Tyrosinemia Type 1 Worldwide. Int. J. Neonatal Screen. 2024, 10, 82.

Overview of European Practices for Management of Tyrosinemia Type 1: Towards European Guidelines.

Overview of European Practices for Management of Tyrosinemia Type 1: Towards European Guidelines.

Hereditary Tyrosinemia Type 1: Success and Challenges in Indian Subcontinent.

Hereditary Tyrosinemia Type 1: Success and Challenges in Indian Subcontinent.

Management of porphyria-like syndrome in tyrosinemia type 1.

Management of porphyria-like syndrome in tyrosinemia type 1.

Evaluation of the Performance of Newborn Screening for Tyrosinemia Type 1 in The Netherlands: Suggestions for Improvements Using Additional Biomarkers in Addition to Succinylacetone.

Evaluation of the Performance of Newborn Screening for Tyrosinemia Type 1 in The Netherlands: Suggestions for Improvements Using Additional Biomarkers in Addition to Succinylacetone.

Integrating Machine Learning and Follow-Up Variables to Improve Early Detection of Hepatocellular Carcinoma in Tyrosinemia Type 1: A Multicenter Study.

Integrating Machine Learning and Follow-Up Variables to Improve Early Detection of Hepatocellular Carcinoma in Tyrosinemia Type 1: A Multicenter Study.

Neurological crisis in tyrosinemia type 1: Essential roles of replacement therapy and nutrition in multidisciplinary management.

Neurological crisis in tyrosinemia type 1: Essential roles of replacement therapy and nutrition in multidisciplinary management.